MSMilan2023: Gemeinsamer Kongress des Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) und des European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Mailand, 11.10.23–13.10.23.
1. Hot Topic 3: MS in the elderly.
2. Free Communications 2: Real world evidence (RWE) – Treatment. Yi Chao Foong: Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
3. Corboy JR et al. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol 2023; 22: 568-77;
https://doi.org/10.1016/S1474-4422(23)00154-0
4. Menge T. Randomisierte Medikamentenabsetzstudie bei über 55-Jährigen mit Multipler Sklerose. Ältere könnten vom Absetzen profitieren. InFo Neurologie + Psychiatrie; 9/2023; https://doi.org/10.1007/s15005-023-3384-7